

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023: HUTCHMED (China) Limited (“[HUTCHMED](#)”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the following awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 3, 2023:-

<u>Award Holders</u>	<u>Number of American depository shares (“ADS”)</u>
Person Discharging Managerial Responsibilities	
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	50,431
Mr Johnny Cheng (Executive Director and Chief Financial Officer)	22,953
Total	73,384

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

(a) Dr Weiguo Su

1 Details of the person discharging managerial responsibilities/person closely associated					
a)	Name Dr Weiguo Su				
2 Reason for the notification					
a)	Position/status Executive Director, Chief Executive Officer and Chief Scientific Officer				
b)	Initial notification/Amendment Initial notification				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name HUTCHMED (China) Limited				
b)	LEI 2138006X34YDQ6OBYE79				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US\$0.10 Identification code ADS ISIN: US44842L1035				
b)	Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP				
c)	Price(s) and volume(s) <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Price(s)</th> <th style="width: 50%;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>50,431 ADS</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	50,431 ADS
Price(s)	Volume(s)				
Nil	50,431 ADS				
d)	Aggregated information — Aggregated volume — Price N/A				
e)	Date of the transaction 2023-03-03				

f)	Place of the transaction	Outside a trading venue
----	--------------------------	-------------------------

(b) Mr Johnny Cheng

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name	Mr Johnny Cheng				
2	Reason for the notification					
a)	Position/status	Executive Director and Chief Financial Officer				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	HUTCHMED (China) Limited				
b)	LEI	2138006X34YDQ6OBYE79				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	ADS each representing five Ordinary Shares of US\$0.10				
	Identification code	ADS ISIN: US44842L1035				
b)	Nature of the transaction	Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>22,953 ADS</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	22,953 ADS
Price(s)	Volume(s)					
Nil	22,953 ADS					
d)	Aggregated information — Aggregated volume — Price	N/A				
e)	Date of the transaction	2023-03-03				
f)	Place of the transaction	Outside a trading venue				

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 306 4490

Media Enquiries

Americas – Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)

bmiles@soleburystat.com

Europe – Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

HUTCHMED@fticonsulting.com

Asia – Zhou Yi, Brunswick

+852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited

+44 (20) 7886 2500